ES2974842T3 - Compuestos y composiciones para el tratamiento de afecciones asociadas a la actividad de nlrp - Google Patents
Compuestos y composiciones para el tratamiento de afecciones asociadas a la actividad de nlrp Download PDFInfo
- Publication number
- ES2974842T3 ES2974842T3 ES19821319T ES19821319T ES2974842T3 ES 2974842 T3 ES2974842 T3 ES 2974842T3 ES 19821319 T ES19821319 T ES 19821319T ES 19821319 T ES19821319 T ES 19821319T ES 2974842 T3 ES2974842 T3 ES 2974842T3
- Authority
- ES
- Spain
- Prior art keywords
- alkyl
- optionally substituted
- aryl
- hydroxy
- nhco
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862760244P | 2018-11-13 | 2018-11-13 | |
| US201862760195P | 2018-11-13 | 2018-11-13 | |
| US201862760248P | 2018-11-13 | 2018-11-13 | |
| PCT/US2019/060772 WO2020102098A1 (en) | 2018-11-13 | 2019-11-11 | Compounds and compositions for treating conditions associated with nlrp activity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2974842T3 true ES2974842T3 (es) | 2024-07-01 |
Family
ID=68916530
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES19821319T Active ES2974842T3 (es) | 2018-11-13 | 2019-11-11 | Compuestos y composiciones para el tratamiento de afecciones asociadas a la actividad de nlrp |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US12421223B2 (enExample) |
| EP (1) | EP3880673B1 (enExample) |
| JP (1) | JP2022506891A (enExample) |
| CN (1) | CN113015730A (enExample) |
| ES (1) | ES2974842T3 (enExample) |
| WO (1) | WO2020102098A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3649112A1 (en) * | 2017-07-07 | 2020-05-13 | Inflazome Limited | Sulfonylureas and sulfonylthioureas as nlrp3 inhibitors |
| US11932630B2 (en) | 2021-04-16 | 2024-03-19 | Novartis Ag | Heteroaryl aminopropanol derivatives |
| US20250243172A1 (en) * | 2022-04-21 | 2025-07-31 | Virginia Commonwealth University | Nlrp3 inflammasome inhibitors and compositions and uses thereof |
| TW202545527A (zh) | 2024-01-16 | 2025-12-01 | 英商諾得瑟拉公司 | Ｎｌｒｐ３及ｇｌｐ－１ａ組合療法 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5116742A (en) | 1986-12-03 | 1992-05-26 | University Patents, Inc. | RNA ribozyme restriction endoribonucleases and methods |
| US4987071A (en) | 1986-12-03 | 1991-01-22 | University Patents, Inc. | RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods |
| CA2065346C (en) | 1989-09-05 | 2005-03-29 | Craig A. Smith | Tumor necrosis factor-.alpha. and-.beta. receptors |
| CA2085297A1 (en) | 1991-12-20 | 1993-06-21 | James Edward Ray | Sulfonimidamides |
| US5705398A (en) | 1994-03-02 | 1998-01-06 | The Scripps Research Institute | Methods for identifying inhibitors of LPS-mediated LBP binding |
| US6090382A (en) | 1996-02-09 | 2000-07-18 | Basf Aktiengesellschaft | Human antibodies that bind human TNFα |
| ATE239041T1 (de) | 1996-02-09 | 2003-05-15 | Basf Ag | Humane antikörper welche an humanen tnfalpha binden |
| PL344004A1 (en) * | 1998-05-05 | 2001-09-10 | Hoffmann La Roche | Pyrazole derivatives as p-38 map kinase inhibitors |
| CN1832928B (zh) * | 2003-06-26 | 2012-07-04 | 诺瓦提斯公司 | 以5元杂环为基础的p38激酶抑制剂 |
| US20080280910A1 (en) * | 2007-03-22 | 2008-11-13 | Keith Allan Menear | Phthalazinone derivatives |
| US8884006B2 (en) | 2011-09-19 | 2014-11-11 | University Of Puerto Rico | Small-molecule inhibitors of Rac1 in metastatic breast cancer |
| US9701689B2 (en) | 2012-11-30 | 2017-07-11 | Kyowa Hakko Kirin Co., Ltd. | Substituted pyridines and pyridazines as CCR10 receptor inhibitors |
| ITMI20131658A1 (it) | 2013-10-08 | 2015-04-09 | Getters Spa | Combinazione di materiali per dispositivi di rilascio di mercurio e dispositivi contenenti detta combinazione di materiali |
| US9714288B2 (en) | 2014-09-30 | 2017-07-25 | The Regents Of The University Of California | Antisense compounds and uses thereof |
| JP6929792B2 (ja) * | 2015-02-16 | 2021-09-01 | ザ ユニバーシティ オブ クィーンズランド | スルホニル尿素及び関連化合物並びにその使用 |
| BR112018008506B8 (pt) * | 2015-10-29 | 2023-12-05 | Merck Sharp & Dohme | Compostos inibidores do fator xia, composição farmacêutica e usos dos mesmos |
| FR3046933B1 (fr) * | 2016-01-25 | 2018-03-02 | Galderma Research & Development | Inhibiteurs nlrp3 pour le traitement des pathologies cutanees inflammatoires |
| US11447460B2 (en) * | 2016-04-18 | 2022-09-20 | Novartis Ag | Compounds and compositions for treating conditions associated with NLRP activity |
| MA44729A (fr) * | 2016-04-18 | 2021-05-12 | Novartis Ag | Composés et compositions pour traiter des états associés à une activité de nlrp |
| EP3445761A1 (en) | 2016-04-19 | 2019-02-27 | Innate Tumor Immunity, Inc. | Nlrp3 modulators |
| KR102521955B1 (ko) * | 2016-06-14 | 2023-04-13 | 브리스톨-마이어스 스큅 컴퍼니 | Apj 수용체 효능제로서의 4-히드록시-3-술포닐피리딘-2(1h)-온 |
| UA126675C2 (uk) | 2017-01-23 | 2023-01-11 | Дженентек, Інк. | Хімічні сполуки як інгібітори активності інтерлейкіну-1 |
| EP3634951B8 (en) | 2017-06-09 | 2024-08-21 | Zydus Lifesciences Limited | Novel substituted sulfoximine compounds |
| JP7412328B2 (ja) | 2017-07-24 | 2024-01-12 | ノバルティス アーゲー | Ｎｌｒｐ活性に関連する状態を治療するための化合物及び組成物 |
| WO2019034697A1 (en) | 2017-08-15 | 2019-02-21 | Inflazome Limited | NOVEL CARBOXAMIDE SULFONAMIDE COMPOUNDS |
| MA53172A (fr) | 2018-07-20 | 2021-05-26 | Hoffmann La Roche | Composés de sulfonimidamide en tant qu'inhibiteurs de l'activité de l'interleukine 1 |
| GB201902327D0 (en) | 2019-02-20 | 2019-04-03 | Inflazome Ltd | Novel compounds |
| PY1975819A (es) | 2018-09-13 | 2020-04-09 | Bayer Ag | Derivados heterocíclicos como plaguicidas.- |
| WO2020150674A1 (en) | 2019-01-18 | 2020-07-23 | Nuvation Bio Inc. | Heterocyclic compounds as adenosine antagonists |
| CN114008030A (zh) | 2019-06-21 | 2022-02-01 | Ac免疫有限公司 | 用作nlrp3调节剂的稠合的1,2-噻唑和1,2-噻嗪 |
-
2019
- 2019-11-11 CN CN201980074378.7A patent/CN113015730A/zh active Pending
- 2019-11-11 US US17/292,891 patent/US12421223B2/en active Active
- 2019-11-11 ES ES19821319T patent/ES2974842T3/es active Active
- 2019-11-11 EP EP19821319.1A patent/EP3880673B1/en active Active
- 2019-11-11 JP JP2021525000A patent/JP2022506891A/ja active Pending
- 2019-11-11 WO PCT/US2019/060772 patent/WO2020102098A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| WO2020102098A1 (en) | 2020-05-22 |
| EP3880673A1 (en) | 2021-09-22 |
| JP2022506891A (ja) | 2022-01-17 |
| US12421223B2 (en) | 2025-09-23 |
| CN113015730A (zh) | 2021-06-22 |
| EP3880673B1 (en) | 2024-01-03 |
| US20230025630A1 (en) | 2023-01-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7654767B2 (ja) | Ｎｌｒｐ活性に関連する状態を治療するための化合物及び組成物 | |
| US20240391884A1 (en) | Compounds and compositions for treating conditions associated with nlrp activity | |
| CN113166065B (zh) | 用于治疗与nlrp活性相关的病症的化合物和组合物 | |
| CN112584899A (zh) | Nlrp调节剂 | |
| ES2957692T3 (es) | Compuestos y composiciones para el tratamiento de afecciones asociadas a la actividad de NLRP | |
| CN112654350A (zh) | 使用nlrp3拮抗剂治疗对tnf抑制剂有抗性的受试者或针对所述患者选择治疗的方法 | |
| US20230063462A1 (en) | Sulfonimidamide compounds and compositions for treating conditions associated with nlrp activity | |
| EP3880673B1 (en) | Compounds and compositions for treating conditions associated with nlrp activity | |
| EP3914583A1 (en) | Compounds and compositions for treating conditions associated with nlrp activity | |
| WO2020010140A1 (en) | Nlrp modulators | |
| CN113227055A (zh) | 用于治疗与nlrp活性相关的病症的化合物和组合物 | |
| US20230079631A1 (en) | Compounds and compositions for treating conditions associated with nlrp activity | |
| HK40103462A (en) | Compounds and compositions for treating conditions associated with nlrp activity | |
| HK40024570A (en) | Compounds and compositions for treating conditions associated with nlrp activity | |
| HK40024570B (en) | Compounds and compositions for treating conditions associated with nlrp activity | |
| CN101291928A (zh) | 4-杂芳甲基取代的酞嗪酮衍生物 |